



ASX / Media Release  
10 February 2022

## Upcoming Presentations at 48<sup>th</sup> Annual NANOS Meeting

---

**Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company)** a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (sustained release Exenatide) for neurological conditions relating to raised intracranial pressure today announces two upcoming oral presentations at the 48<sup>th</sup> Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS) on 12-17 February 2022 in Austin, Texas.

*“Intra-Cranial Pressure in Idiopathic Intracranial Hypertension, Insights From Long-Term Telemetric Monitoring”* will be presented By Professor Alex Sinclair, Invex Executive Director and Chief Scientific Officer and Clinician Scientist and Neurology Consultant in the Metabolic Neurology Group at the Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, The University of Birmingham. This study complements the data previously reported from the Phase II Pressure trial in Idiopathic Intracranial Hypertension (IIH) and uses implanted telemetric intracranial pressure (ICP) monitoring to enable greater understanding of ICP regulation.

*“A Randomized Controlled, Trial of the GLP-1 Receptor Agonist Exenatide in Idiopathic Intracranial Hypertension”* will be presented by Dr James L. Mitchell, at the Institute of Metabolism and Systems Research, University of Birmingham, UK and member of Prof. Sinclair’s research group. The results of the Phase II Pressure Trial in IIH have underpinned Invex Therapeutics’ planned Phase III clinical development program. This abstract has also nominated as a NANOS 2022 Best Abstract.

Further details of the conference can be located at the NANOS Meeting site [here](#).

- ENDS -

***This release dated 10 February 2022 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.***

---

### For more information, please contact:

#### Company/Investors

Dr Thomas Duthy  
Executive Director  
[tduthy@invextherapeutics.com](mailto:tduthy@invextherapeutics.com)  
+61 402 493 727

#### Media

Margie Livingston  
Ignite Communications  
[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)  
+61 438 661 131

To subscribe to Invex email alerts, please visit [www.invextherapeutics.com](http://www.invextherapeutics.com) and follow us on Twitter @InvexThera\_ASX

## About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. [www.invextherapeutics.com](http://www.invextherapeutics.com).

## About Idiopathic Intracranial Hypertension (IIH)

---

IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve. The usual age of onset is 20-30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.

## About Presendin™

---

Presendin™ is a once per week, sub-cutaneous, sustained release (SR) Exenatide microsphere formulation originally developed by Peptron, Inc. (KOSDAQ: 087010). In September 2021 Invex entered into an exclusive collaboration, manufacturing and supply agreement with Peptron for Presendin™ in IIH for all major markets, with the exception of South Korea.

Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which is currently approved for the treatment of type 2 diabetes. In 2017, Invex received orphan drug designation for Exenatide in IIH from the US Food and Drug Administration and European Medicines Agency.